MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on every 2026 Missouri Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Missouri cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
IL-17, IL-23 and IL-12/23 biologics by 2026 Missouri Part D plan
DrugWellcare Value Script$9.60/moS4802-152Wellcare Classic$10.70/moS4802-072Humana Basic Rx Plan$16.50/moS5884-140Humana Value Rx Plan$33.70/moS5884-197HealthSpring Extra Rx$70.70/moS5617-368AARP Medicare Rx Saver from UHC$71.90/moS5921-363HealthSpring Assurance Rx$74.30/moS5617-088SilverScript Choice$94.90/moS5601-036AARP Medicare Rx Preferred from UHC$125.40/moS5921-399Humana Premier Rx Plan$126.40/moS5884-164
StelaraustekinumabNot coveredNot coveredTier 5PA25%QL 1.5/84dTier 5PA26%QL 1.5/84dTier 5PA25%QL 0.5/28dNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 0.5/28dNot coveredTier 5PA33%QL 1.5/84d
ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and othersNot coveredNot coveredTier 5PA25%QL 1.5/84dTier 5PA26%QL 1.5/84dTier 5PA25%QL 0.5/28dNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 0.5/28dNot coveredTier 5PA33%QL 1.5/84d
Wezlanaustekinumab-auubNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Selarsdiustekinumab-aeknNot coveredNot coveredNot coveredNot coveredTier 3PA17%QL 0.5/28dNot coveredTier 3PA20%QL 0.5/28dNot coveredNot coveredNot covered
SkyrizirisankizumabTier 5PA25%QL 6/365dTier 5PA25%QL 6/365dTier 5PA25%QL 2/84dTier 5PA26%QL 2/84dTier 5PA25%QL 2/28dTier 5PA25%QL 1/28dTier 5PA25%QL 2/28dTier 5PA25%QL 6/365dTier 5PA31%QL 1/28dTier 5PA33%QL 2/84d
TremfyaguselkumabTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 3/84dTier 5PA26%QL 3/84dTier 5PA25%QL 2/28dTier 5PA25%Tier 5PA25%QL 2/28dTier 5PA25%QL 1/28dTier 5PA31%Tier 5PA33%QL 3/84d
CosentyxsecukinumabTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/30dTier 5PA25%QL 10/28dNot coveredTier 5PA31%QL 10/30dTier 5PA33%QL 8/28d
TaltzixekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
BimzelxbimekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 4/28dNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.